Recovery after a myasthenia gravis (MG) exacerbation — a flare up or sudden worsening of disease symptoms — may take many months, even with the newer treatment options now available to MG patients. That’s according to a small study in Germany that followed 12 people with MG, treated with…
News
People with myasthenia gravis (MG) have higher psychological distress, including depression and anxiety, more frequent sleep problems, and greater cognitive difficulties than healthy people, according to a study in Italy. In addition, more severe disease and treatment with higher doses of corticosteroids were independent predictors of psychiatric symptoms…
Four weekly under-the-skin injections of Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) led to a marked reduction in double vision and drooping eyelids in adults with ocular myasthenia gravis (MG), according to top-line Phase 3 results. These findings come from the global Phase 3 ADAPT OCULUS clinical trial (NCT06558279),…
Next week, researchers, clinicians, industry leaders, and families will gather at the 2026 MDA Clinical & Scientific Conference, hosted by the Muscular Dystrophy Association (MDA), to discuss the latest advances in neuromuscular disease research and care. Ahead of the event, Bionews, the parent company of this site, sat…
While certain medications are typically avoided in myasthenia gravis (MG), a large-scale study from France suggests that cholesterol-lowering statins may actually reduce the overall risk of death in these patients. The research indicates that although statins can slightly increase the short-term chance of a severe symptom flare-up, their…
More than two-thirds of people with clinically stable myasthenia gravis (MG) have problems with disturbed sleep, with resulting negative effects on their quality of life, a survey study of hundreds of MG patients in China has found. Further, those with sleep problems were significantly more likely to have obstructive…
Researchers in the U.K. have identified a distinct immune profile in adults with myasthenia gravis (MG) whose disease does not respond to standard therapies. “Understanding these immune differences brings us closer to predicting how patients will respond to therapy and to developing more targeted, personalised treatment approaches,” Madhvi Menon,…
Less than half of Americans newly diagnosed with myasthenia gravis (MG) are receiving the recommended blood tests to confirm their condition, even though these results are vital for choosing the appropriate treatment. According to new research using real-world U.S. insurance data, many patients are starting MG-specific therapies, including…
Aiming to address a persistent gap in myasthenia gravis (MG) research, Vitaccess is teaming up with the Myasthenia Gravis Foundation of America (MGFA) to expand real-world data collection in MG. As part of the new exclusive agreement, MGFA will become the official collaborator for the Vitaccess Real MG…
Uplizna (inebilizumab), Amgen’s infusion therapy for adults with generalized myasthenia gravis (gMG) who are positive for antibodies targeting acetylcholine receptor (AChR) or muscle-specific kinase (MuSK), is now approved for use in the European Union. The decision by the European Commission — which applies to all EU member states…
Recent Posts
- My twin’s drooping eyes remind me to do better at using my ears
- Does myasthenia gravis really have that much power over me?
- Recovery after MG flares takes many months, even with newer meds: Study
- Severe MG, high corticosteroid dose tied to worse psychological distress
- I’m limiting my news consumption to better manage my health with MG